Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages
View abstract on PubMed
Summary
This summary is machine-generated.Pancreatic cancer progression from initial detection to advanced stages appears rapid, despite mathematical models suggesting years for growth. This study found earlier diagnosis ages for smaller, less advanced pancreatic ductal adenocarcinomas.
Area Of Science
- Oncology
- Cancer Research
- Epidemiology
Background
- Pancreatic ductal adenocarcinoma (PDAC) is often viewed as a rapidly progressing disease.
- Mathematical models suggest a long preclinical development period for PDAC.
- Understanding PDAC progression through clinical stages is crucial for treatment strategies.
Purpose Of The Study
- To estimate the time it takes for pancreatic cancer to progress through different tumor, node, metastasis (TNM) stages.
- To compare the mean age of patients diagnosed with pancreatic cancers of varying sizes and stages.
Main Methods
- Analysis of patient age, tumor size, stage, and demographic data for 13,131 patients with PDAC from the National Cancer Institute's SEER database.
- Utilized multiple linear regression models for age, adjusting for ethnicity, gender, tumor location, and neoplastic grades.
Main Results
- Earlier age at diagnosis was associated with African-American ethnicity and male gender.
- Patients with Stage I PDAC were diagnosed at a younger mean age (64.8 years) compared to Stage IV (p=0.001).
- Smaller tumors (T1) were associated with younger diagnosis ages than larger tumors (T3/T4) among patients without distant metastases (p=0.03).
Conclusions
- Findings support the hypothesis that PDAC progression is rapid once clinically detectable.
- The clinical progression from early-stage to advanced-stage pancreatic cancer appears to occur quickly.